2007년도 제16차 대한임상약리학회 및 한국제약의학회 추계학술대회

구연 15

Genetic Variants of SLC22A2 (Organic Cation Transporter 2, OCT2) Significantly Influence on the Disposition of Metformin

송임숙, 신호정, 심언정, 정일선, 김우영, 손지홍, 신재국

인제대학교 의과대학 약리학교실, 부산백병원 임상약리학과

The genetic variants of SLC22A2 (OCT2) were evaluated for their contribution to the pharmacokinetic variation of metformin, a substrate of OCT2, especially on its renal elimination in vitro and in vivo. The intrinsic clearance of metformin was decreased by 68.6%, 60.1%, and 39.6% in HEK293 cells overexpressing SLC22A2 variants, SLC22A2-T199I, -T201M, and -A270S, respectively, compared with that of wild-type OCT2. After administration of single oral dose of 500mg metformin to 26 healthy subjects whose SLC22A2 genotypes were predetermined, plasma and urine concentrations were measured for 12h. The SLC22A2 variant genotypes showed significant difference of metformin pharmacokinetics compared to the subjects with wild genotype, with higher Cmax and AUC (P<0.01) and lower CL/F, Vd/F (P<0.05), and renal clearance (P < 0.01), suggesting that decreased transport function of OCT2 variants resulted in reduced renal clearance, and consequently increased plasma concentrations of metformin. In conclusion, SLC22A2 genetic variants of SLC22A2 seem to be responsible for the inter-individual variation of metformin disposition and should be considered for the prediction of metformin dose.